Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06885099 · ClinicalTrials.gov registry record · NA
Ease of Use Study of the FemPulse System
A NA study, sponsored by FemPulse Corporation.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT06885099: Completed NA study, sponsored by FemPulse Corporation.
NCT06885099 is a NA study that has completed, run by FemPulse Corporation. The registered enrollment target is 11 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06885099, a NA study, has completed, sponsored by FemPulse Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
The objective of the study is to demonstrate that the FemPulse System can be used as indicated
Primary Outcome
A survery will be conducted to determine the overall usability of the system
Interventions
- DEVICE FemPulse System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2025-02-11 |
| Est. Completion | 2025-07-31 |
| Phase | NA |
What the finished NCT06885099 record still lists
NCT06885099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which FemPulse System is the first listed.
NCT06885099 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06885099 about?
NCT06885099 is a clinical study titled "Ease of Use Study of the FemPulse System". The objective of the study is to demonstrate that the FemPulse System can be used as indicated
What is the current status of trial NCT06885099?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2025-02-11. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT06885099?
The interventions under investigation include: FemPulse System (DEVICE).
Who is sponsoring clinical trial NCT06885099?
This trial is sponsored by FemPulse Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06885099's enrollment target sits among peer trials
11 1927th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI